Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

COVID lockdown reopening

Number of TAVR sites has nearly tripled in recent years—but quality issues remain

While the improved access is clearly beneficial, researchers did uncover potential issues that will need to be addressed. 

New self-expanding TAVR system gains FDA approval

A full launch of the new system is scheduled for early 2022. 

Thumbnail

LAAO outcomes significantly worse among women

Researchers tracked data from more than 49,000 patients who underwent LAAO from January 2016 to June 2019.

Abbott’s LAA closure solution for AFib patients gains FDA approval

The device has already been approved in other parts of the world, including Europe. 

Thumbnail

Repeat TAVR leads to better short-term outcomes than TAVR explantation

Repeat TAVR is expected to grow more and more common as time goes on, making it especially important to study its impact on patient outcomes.

Thumbnail

CAC scores help predict TAVR mortality

The analysis, published in Radiology, included more than 300 patients who presented with severe aortic stenosis.

Thumbnail

TMVR outcomes suffer when patients have heart failure and diabetes—but benefits remain

Overall, the authors emphasized, TMVR helped heart failure patients with and without diabetes.

Next-day discharge after TMVR is on the rise

By 2018, nearly half of all TMVR patients were going home the very next day. Outcomes for these patients have been consistently positive. 

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.